About John D Ash
Dr. Ash is the Francis M. Bullard Eminent Scholar Chair in Ophthalmic Sciences, and is an Associate Professor of Ophthalmology, College of Medicine, at the University of Florida.
Dr. Ash received his Ph.D. from the Ohio State University Biochemistry Program in 1994 and completed postdoctoral training in the Cell Biology Department at Baylor College of Medicine, in Houston, Texas, and began his faculty career at the University of Oklahoma Health Sciences Center, Oklahoma. Dr. Ash is also a Visiting Professor at the Dalian Medical University, Dalian China. Dr. Ash has written and published 60 manuscripts including research articles, book chapters and invited reviews, and has edited four books. Dr. Ash’s research is focused on mechanisms of retinal degeneration and neuroprotection, with a focus on degeneration of photoreceptors and the RPE. This work also has a strong translational component and has led to the creation of two new neuroprotective drugs and the identification of 3 novel pathways to induce neuroprotection pharmacologically. Dr. Ash’s work has led to intellectual disclosure filings, and the filing of one U.S. Patent Application. He is currently an Executive editor for Experimental Eye research and a Scientific Review Editor for Molecular Vision. Dr. Ash is an active reviewer for these journals as well as Investigative Ophthalmology & Visual Science. In 2009, Dr. Ash received a research award from Hope for Vision, and in 2010 he received a Lew R. Wasserman Merit award from Research to Prevent Blindness, Inc. Dr. Ash has received grants from the National Institutes of Health, the Foundation Fighting Blindness, Research to Prevent Blindness, Inc., Hope for Vision, and the American Diabetes Association. Dr. Ash has served on the Program and Advocacy committees of the Association for Research in Vision and Ophthalmology. Dr. Ash has served on the scientific review panel for Fight For Sight (2005-2008) and is currently serving on the Scientific Advisory Board of the Foundation Fighting Blindness (Columbia, MD) where he chairs the review committee on Novel Medical Therapies Program. He also serves on the scientific review panel for the Macular Degeneration program of the BrightFocus Foundation (formerly the American Health Assistance Foundation, Clarksburg, MD).